Several PRMT6-selective inhibitors, including MS117, SGC-6870, EPZ020411, and the natural compound licochalcone A, have demonstrated therapeutic potential in various solid tumors, including glioblastoma, lung, gastric, and breast cancers [268, 562–564]. Here, PRMT6 is linked to breast carcinoma.